• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ASMB

    Assembly Biosciences Inc.

    Subscribe to $ASMB
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.

    IPO Year: 2010

    Exchange: NASDAQ

    Website: assemblybio.com

    Recent Analyst Ratings for Assembly Biosciences Inc.

    DatePrice TargetRatingAnalyst
    3/25/2025$31.00Buy
    Guggenheim
    9/20/2024$2.00 → $35.00Hold → Buy
    Jefferies
    9/13/2021$3.50Neutral
    HC Wainwright & Co.
    9/2/2021Outperform → Market Perform
    William Blair
    See more ratings

    Assembly Biosciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/eve

      5/27/25 4:05:00 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

      – Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted at ICAR, ESCMID and EASL 2025 – SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent updates for the first quarter ended March 31, 2025. "We continue the strong progress across our antiviral portfolio and remain on track for the multiple key clin

      5/8/25 4:05:00 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

      – Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2024, and recent highlights. "We are well-positioned to deliver important clinic

      3/20/25 4:05:00 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

      – Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate. This Phase 1a study w

      2/26/25 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

      – ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose – – Assembly Bio to move ABI-1179 directly into Phase 1b portion of the ongoing Phase 1a/b study in participants with recurrent genital herpes – – Phase 1b to run concurrently with ongoing Phase 1b study for ABI-5366, with interim data for both candidates anticipated in fall 2025 – SOUTH SAN FRANCISCO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announce

      2/20/25 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

      – ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction of 2.9 log IU/mL in plasma HBV DNA over 28 days of treatment – – Enrollment in final cohort of 400 mg ongoing with data anticipated in 1H 2025 – SOUTH SAN FRANCISCO, Calif., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced encouraging interim safety, pharmacokinetic (PK) and efficacy results from participants with chronic hepatitis B vi

      12/26/24 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

      —Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026— —Additional equity investment raises Gilead's ownership stake in Assembly Bio to 29.9%— –Funding supports pipeline progress, including amendment to accelerate clinical development of Assembly Bio's novel small molecule hepatitis D virus candidate ABI-6250— SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced an equity investment

      12/19/24 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

      Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing First participants dosed in Phase 1b trial evaluating ABI-5366 in individuals with recurrent genital herpes with interim data expected in first half of 2025Phase 1b trial for ABI-4334, a next-generation highly potent capsid assembly modulator candidate, ongoing in participants with chronic HBV with interim data expected by end of yearABI-1179 and ABI-6250 candidates on track to enter clinic by end of year SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences

      11/7/24 4:05:00 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

      – ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both dosing schedules will be explored in the Phase 1b portion of the study – – Screening of participants with recurrent genital herpes is now underway for Phase 1b – SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced positive interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoin

      9/23/24 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

      SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a next-generation capsid assembly modulator (CAM) candidate in development for the treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV (cHBV) infection is a leading cause of chronic liver disease and liver transplants globally, with the World Health Organization estimating that over one million people died in 2022 from HBV-related causes. Current treatments are lifelong and reduce, but d

      6/18/24 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Assembly Biosciences Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Assembly Biosciences Inc.

      10-Q - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      5/8/25 4:15:34 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      5/8/25 4:10:09 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Assembly Biosciences Inc.

      DEFA14A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      4/23/25 4:18:42 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Assembly Biosciences Inc.

      DEF 14A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      4/23/25 4:10:15 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Assembly Biosciences Inc.

      EFFECT - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      4/2/25 12:15:22 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Assembly Biosciences Inc.

      S-3 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      3/20/25 4:48:09 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Assembly Biosciences Inc.

      10-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      3/20/25 4:15:31 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      3/20/25 4:10:11 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      2/20/25 4:05:09 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      1/3/25 4:05:11 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Assembly Biosciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mchutchison John G sold $7,455 worth of shares (757 units at $9.85), decreasing direct ownership by 4% to 18,347 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      4/15/25 5:30:04 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Delaney William E Iv

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      4/1/25 4:05:11 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Manufacturing Officer White Nicole S sold $1,940 worth of shares (197 units at $9.85), decreasing direct ownership by 2% to 11,674 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      4/1/25 4:05:06 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Bjorkquist Jeanette M was granted 1,655 shares and sold $1,773 worth of shares (180 units at $9.85), increasing direct ownership by 47% to 4,617 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      4/1/25 4:05:10 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Okazaki Jason A sold $3,496 worth of shares (355 units at $9.85), decreasing direct ownership by 2% to 14,757 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      4/1/25 4:05:07 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Gaggar Anuj

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      4/1/25 4:05:03 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Houghton Michael bought $49,998 worth of shares (3,202 units at $15.61) (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      12/31/24 4:24:14 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $20,098,464 worth of shares (940,499 units at $21.37), increasing direct ownership by 74% to 2,209,471 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      12/23/24 8:26:39 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Schornstein Alexander bought $371,994 worth of shares (25,000 units at $14.88), increasing direct ownership by 4% to 728,113 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      11/26/24 9:15:02 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Manufacturing Officer White Nicole S sold $652 worth of shares (40 units at $16.29), decreasing direct ownership by 0.34% to 11,871 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      11/19/24 4:05:03 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Assembly Biosciences Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Houghton Michael bought $49,998 worth of shares (3,202 units at $15.61) (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      12/31/24 4:24:14 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $20,098,464 worth of shares (940,499 units at $21.37), increasing direct ownership by 74% to 2,209,471 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      12/23/24 8:26:39 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Schornstein Alexander bought $371,994 worth of shares (25,000 units at $14.88), increasing direct ownership by 4% to 728,113 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      11/26/24 9:15:02 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Schornstein Alexander bought $145,800 worth of shares (10,000 units at $14.58), increasing direct ownership by 1% to 703,113 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      10/9/24 9:15:03 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Schornstein Alexander bought $111,631 worth of shares (9,000 units at $12.40), increasing direct ownership by 1% to 693,113 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      7/8/24 10:48:47 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought 179,500 shares, increasing direct ownership by 16% to 1,268,972 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      6/20/24 8:31:31 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schornstein Alexander bought $511,264 worth of shares (645,080 units at $0.79), increasing direct ownership by 9% to 8,209,372 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      1/19/24 11:01:21 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schornstein Alexander bought $282,100 worth of shares (400,000 units at $0.71), increasing direct ownership by 6% to 7,564,292 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      11/22/23 4:10:27 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Assembly Biosciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Assembly Biosciences Inc.

      SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      11/14/24 3:22:29 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

      SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      6/24/24 4:28:09 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

      SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      6/20/24 8:35:37 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Assembly Biosciences Inc. (Amendment)

      SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      11/22/23 4:12:26 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Assembly Biosciences Inc. (Amendment)

      SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      11/3/23 4:05:03 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Assembly Biosciences Inc.

      SC 13D - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      10/31/23 4:19:51 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Assembly Biosciences Inc.

      SC 13D - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      10/25/23 5:18:12 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Assembly Biosciences Inc. (Amendment)

      SC 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      2/14/23 8:26:39 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Assembly Biosciences Inc. (Amendment)

      SC 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      2/14/22 2:45:37 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Assembly Biosciences Inc. (Amendment)

      SC 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      2/14/22 8:55:32 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Assembly Biosciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Assembly Biosciences with a new price target

      Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00

      3/25/25 8:26:24 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences upgraded by Jefferies with a new price target

      Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously

      9/20/24 7:32:14 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Assembly Biosciences with a new price target

      HC Wainwright & Co. initiated coverage of Assembly Biosciences with a rating of Neutral and set a new price target of $3.50

      9/13/21 6:42:05 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences downgraded by William Blair

      William Blair downgraded Assembly Biosciences from Outperform to Market Perform

      9/2/21 6:13:18 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Assembly Biosciences with a new price target

      SVB Leerink reiterated coverage of Assembly Biosciences with a rating of Market Perform and set a new price target of $7.00 from $8.00 previously

      5/10/21 6:55:35 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences downgraded by SVB Leerink

      SVB Leerink downgraded Assembly Biosciences from Outperform to Mkt Perform

      3/23/21 7:30:41 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Assembly Biosciences from Outperform to Market Perform and set a new price target of $8.00 from $9.00 previously

      3/23/21 7:03:46 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist reiterated coverage on Assembly Biosciences with a new price target

      Truist reiterated coverage of Assembly Biosciences with a rating of and set a new price target of $15.00 from $45.00 previously

      3/2/21 11:02:19 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird resumed coverage on Assembly Biosciences

      Robert W. Baird resumed coverage of Assembly Biosciences with a rating of Buy

      2/28/21 10:58:34 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho resumed coverage on Assembly Biosciences with a new price target

      Mizuho resumed coverage of Assembly Biosciences with a rating of Buy and set a new price target of $13.00

      2/26/21 12:04:34 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Assembly Biosciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

      -- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi

      11/8/23 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

      −ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv

      2/15/23 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

      Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

      1/17/23 7:00:00 AM ET
      $ASMB
      $PRDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334

      In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNAInitial ABI-4334 Phase 1a single-dose 30 mg cohort demonstrated pharmacokinetic profile supportive of once-daily oral dosing and provides early indication that ABI-4334's very high potency seen preclinically can be accessed clinicallyNo serious adverse events or significant laboratory abnormalities including alanine aminotransferase (ALT) elevation were observed in either study Given potent antiviral activity in the initial 50 mg cohort, second 25 mg cohort ongoing in

      12/19/22 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334

      Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334 (4334). 4334 is an investigational next-generation core inhibitor that is optimized for significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production versus first-generation

      11/14/22 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

      Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent, orally bioavailable viral entry inhibitors for HBV and hepatitis D virus (HDV) First data presented on novel series of orally bioavailable small molecule interferon-a receptor (IFNAR) agonists designed to inhibit HBV and engage the immune system with potential to offer improved tolerability SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovati

      11/4/22 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor

      SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John G. McHutchison, AO, MD, chief executive officer (CEO), will retire as CEO at the end of 2022. Dr. McHutchison will continue to serve on Assembly Bio's Board of Directors, including assuming the role of chairman of the Science and Technology Committee. Assembly Bio's Board of Directors has unanimously elected Jason A. Okazaki, the company's current president and chief operating officer (COO), as chief executive of

      10/5/22 4:05:00 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care